GoodRx Misses Earnings Estimates, Stock Plummets in Q2 Report

GoodRx’s Q2 CY2025 Performance and Financial Overview

GoodRx (NASDAQ:GDRX) reported its financial results for the second quarter of CY2025, revealing a modest sales increase of 1.2% year-on-year to $203.1 million. The company's non-GAAP profit of $0.09 per share aligned with analysts' expectations. However, several key metrics fell short of projections, raising questions about the company's future performance.

Key Metrics from Q2 CY2025

• Revenue: $203.1 million, which was below analyst estimates of $205.7 million, representing a 1.2% year-on-year growth and a 1.3% miss.
• Adjusted EPS: $0.09, matching analyst forecasts of $0.10.
• Adjusted EBITDA: $69.4 million, slightly under the estimated $70.62 million, resulting in a 34.2% margin and a 1.7% shortfall.
• Full-Year EBITDA Guidance: Projected at $270 million at the midpoint, falling below analyst expectations of $279.7 million.
• Operating Margin: Improved to 13.2%, up from 9.9% in the same quarter last year.
• Free Cash Flow Margin: Remained stable at 4.7%, similar to the previous year.
• Customer Base: Decreased to 5.7 million, down from 6.4 million in the prior quarter.
• Market Capitalization: $1.67 billion.

Company Background and Mission

Founded in 2011, GoodRx aims to address the issue of high prescription drug costs in the United States by offering a digital platform that allows consumers to compare prices and access discount codes for medications. This mission has positioned the company as a key player in the healthcare technology sector.

Revenue Growth Trends

Over the past five years, GoodRx has maintained an annualized revenue growth rate of 11.1%, which is above the average for healthcare companies. This indicates that the company's offerings have resonated well with customers. However, recent performance shows a slowdown, with two-year revenue growth at 3.6%, below the five-year trend.

Analyzing customer data reveals that the company had 5.7 million customers in the latest quarter, with an average year-on-year growth of 2.9% over the last two years. This suggests that the average customer spending remained relatively consistent during this period.

In Q2, the company's revenue grew by 1.2% year-on-year to $203.1 million, missing Wall Street estimates. Analysts expect a 4.8% revenue growth over the next 12 months, which is in line with the two-year growth rate but still below the sector average.

Adjusted Operating Margin Analysis

GoodRx has demonstrated efficiency over the past five years, with an average adjusted operating margin of 25.9%. However, this margin has declined by 5.8 percentage points over the same period. On a two-year basis, the margin improved by 2.7 percentage points. In Q2, the adjusted operating margin was 25.8%, matching the same quarter last year, indicating a stable cost structure.

Earnings Per Share Performance

GoodRx's earnings per share (EPS) grew at a compounded annual rate of 3.1% over the last five years, which is lower than its 11.1% revenue growth. This suggests that the company became less profitable on a per-share basis as it expanded.

In Q2, the company reported an adjusted EPS of $0.09, up from $0.08 in the same quarter last year. Despite this increase, the figure missed analyst expectations. Looking ahead, analysts forecast a full-year EPS of $0.35, with a target of $0.42 for the next 12 months.

Key Takeaways from Q2 Results

The Q2 results did not present many positive aspects, with both EPS and customer numbers falling short of expectations. As a result, the stock price dropped by 5.2% to $4.12 following the report.

While one quarter does not define a company's overall quality, investors are evaluating whether GoodRx is a viable investment at its current valuation. The focus remains on longer-term fundamentals and how the company can improve its performance in the coming quarters.

For those interested in further analysis, a comprehensive research report is available for free, providing actionable insights into the company's potential.